Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Core Insights - Tivic Health Systems, Inc. will present at the 3rd Annual DealFlow Discovery Conference, focusing on updates regarding its lead drug candidate, Entolimod, and its commercialization strategy [2][3]. Company Updates - The presentation will cover key milestones such as the successful scale-up of Entolimod manufacturing and progress towards cGMP manufacturing for a Biologics License Application (BLA) submission to the FDA [3]. - The strategic integration of Velocity Bioworks, a contract development and manufacturing organization (CDMO), is expected to enhance commercial readiness [3][12]. - Outcomes from a recent TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA) will also be discussed [3]. Product Information - Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist aimed at treating Acute Radiation Syndrome (ARS), showing promising results in animal trials, including improved survival rates and gastrointestinal recovery [10][11]. - The drug is in late-stage development, with additional applications being explored for conditions like Neutropenia and lymphocyte exhaustion [11]. Conference Details - The DealFlow Discovery Conference is a significant event for connecting high-growth companies with the investment community, featuring presentations, networking, and opportunities for capital raising [4][5]. - The conference will take place on January 28-29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, NJ [7].